Nephrogen

Nephrogen is a biotech company developing curative gene therapies for kidney and pancreatic diseases.

Operating in artificial intelligence and machine learning based in New York, NY, USA, Nephrogen operates.

Profile

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies.

Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.

Within the artificial intelligence and machine learning space, the company focuses on its core offering rather than a broad product line.

New York, NY, USA is where the company is located.

Directory data places it at the Summer 2020 stage.

The company reports a headcount in the 5 range.

Website: www.nephrogenbiotech.com